BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34334704)

  • 1. FOVEAL MÜLLER CELL CONE AS A PROGNOSTIC OPTICAL COHERENCE TOMOGRAPHY BIOMARKER FOR INITIAL RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN CYSTOID DIABETIC MACULAR EDEMA.
    Choi M; Yun C; Oh JH; Kim SW
    Retina; 2022 Jan; 42(1):129-137. PubMed ID: 34334704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes With Diabetic Macular Edema and Retinal Vein Occlusion.
    Ghasemi Falavarjani K; Iafe NA; Hubschman JP; Tsui I; Sadda SR; Sarraf D
    Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):30-34. PubMed ID: 28114569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema.
    Murakami T; Suzuma K; Uji A; Yoshitake S; Dodo Y; Fujimoto M; Yoshitake T; Miwa Y; Yoshimura N
    Jpn J Ophthalmol; 2018 May; 62(3):292-301. PubMed ID: 29460019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macular Hole Formation after Intravitreal Injection of Bevacizumab for Diabetic Macular Edema.
    Lee YJ; Kim M
    Korean J Ophthalmol; 2019 Apr; 33(2):198-199. PubMed ID: 30977331
    [No Abstract]   [Full Text] [Related]  

  • 7. Vessel Density Changes on Optical Coherence Tomography Angiography after Vascular Endothelial Growth Factor Inhibitor Treatment for Diabetic Macular Edema.
    Cheong KX; Lee SY; Ang M; Teo KYC
    Turk J Ophthalmol; 2020 Dec; 50(6):343-350. PubMed ID: 33389934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study.
    Karst SG; Deak GG; Gerendas BS; Waldstein SM; Lammer J; Simader C; Guerin T; Schmidt-Erfurth UM
    JAMA Ophthalmol; 2018 Apr; 136(4):315-321. PubMed ID: 29494727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
    Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
    Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
    Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
    Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
    Tang F; Qin X; Lu J; Song P; Li M; Ma X
    Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO DETECT MACULAR CAPILLARY ISCHEMIA IN PATIENTS WITH INNER RETINAL CHANGES AFTER RESOLVED DIABETIC MACULAR EDEMA.
    Moein HR; Novais EA; Rebhun CB; Cole ED; Louzada RN; Witkin AJ; Baumal CR; Duker JS; Waheed NK
    Retina; 2018 Dec; 38(12):2277-2284. PubMed ID: 29068912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
    Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
    Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foveal Microvascular Integrity Association With Anti-VEGF Treatment Response for Diabetic Macular Edema.
    Huang WH; Lai CC; Chuang LH; Huang JC; Wu CH; Lin YT; Yeung L
    Invest Ophthalmol Vis Sci; 2021 Jul; 62(9):41. PubMed ID: 34323921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CORRELATION OF OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI WITH VISUAL OUTCOMES IN DIFFERENT PATTERNS OF DIABETIC MACULAR EDEMA.
    Kang JW; Chung H; Chan Kim H
    Retina; 2016 Sep; 36(9):1630-9. PubMed ID: 26900741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
    Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial.
    Mehta H; Fraser-Bell S; Yeung A; Campain A; Lim LL; Quin GJ; McAllister IL; Keane PA; Gillies MC
    Br J Ophthalmol; 2016 Jul; 100(7):1000-1004. PubMed ID: 26537156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
    Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.